Skip to main content

New Releases: Apr 22, 2009

Premium

AltheaDx this week announced the launch of its Affymetrix Drug Metabolizing Enzymes & Transporter genotyping microarray service.

According to the company, the new service provides biopharmaceutical clients with "a way to measure the genetics of drug metabolism in clinical trial patients — giving drug developers the opportunity to select patients that are more likely to respond."

AltheaDx will compile patients' genetic data in a report for customers, and this information can then be integrated into existing clinical trial protocols.

"The DMET report includes biomarker analysis from all US Food and Drug Administration-validated genes and more than 150 well-documented biomarkers known to impact drug metabolism," the company said in a statement. "In addition to these proven biomarkers, the report contains information on a total of 1,936 genetic variants in 225 enzyme and transporter genes, making it a useful tool for exploratory pharmacokinetic studies to identify new biomarkers such as variants in CYP4F2, recently discovered using DMET to explain 8 percent of warfarin dosing variability."

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.